Clinicopathological and prognostic significance of SDC1 overexpression in breast cancer
Metrics: PDF 680 views | HTML 1183 views | ?
Xiangrong Cui1,2,3, Xuan Jing5, Qin Yi1,2,3, Chunlan Long1,2,3, Jie Tian4, Jing Zhu1,2,3
1Pediatric Research Institute, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing 400014, China
2China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing 400014, China
3Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
4Cardiovascular Department (Internal Medicine), Children’s Hospital of Chongqing Medical University, Chongqing 400014, China
5Clinical Laboratory, Shanxi Province People’s Hospital, Taiyuan 030000, China
Jing Zhu, email: firstname.lastname@example.org
Keywords: syndecan-1; breast cancer; bioinformatic analyses; prognosis
Received: October 11, 2017 Accepted: November 13, 2017 Published: November 30, 2017
Background: Breast cancer is the leading cause of cancer death among global women, and its early diagnosis and treatment are very urgent. Syndecan-1 (SDC1) is a heparin sulfate proteoglycan, which has been linked with the prognosis and treatment response in a various tumor type. To investigate whether SDC1 can serve as a prognostic indictor in breast cancer, bioinformatic analyses were performed in the present study.
Methods: SDC1 expression was assessed using Oncomine analysis. Kaplan-Meier Plotter and bc-GenExMiner were performed to identify the prognostic roles of SDC1 in breast cancer. COSMIC analysis and cBioPortal database were performed to analysis the mutations of SDC1. The heat map and methylation status of SDC1 were identified by performing the UCSC.
Results: We found that SDC1 was more frequently overexpressed in breast cancer than their normal tissues and its expression might be negatively related with some CpG sites. Meanwhile, pooled data suggested that SDC1 mRNA expression is associated worse prognosis of breast cancer. Following data mining in multiple big databases confirmed a positive correlation between SDC1 mRNA expression and PLAU mRNA expression in breast cancer tissues. In addition, high SDC1 expression is associated with increased risked of age, nodal, HER2 and higher SBR grade status.
Conclusion: Our findings suggest that overexpressed SDC1 was identified in breast cancer than in matched normal tissues and is associated with methylation status of SDC1 promoter. Additionally, SDC1 is positively associated with PLAU and might act as a potential prognostic indicator for breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.